Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESP Block vs TPI for Chronic Thoracic Myofascial Pain
NCT07632820Phase 4Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine hydrochloride 0.75% injection in Thoracic myofascial pain syndrome (TMPS) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Numeric Rating Scale at 6 weeks. Started Aug 2026; status: recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
Thoracic myofascial pain syndrome (TMPS)
Beyond the preview
Go deeper on NCT07632820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632820.